- Home
- APM
as 08-13-2025 2:30pm EST
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
Upcoming Earnings Alert:
Get ready for potential market movements as Aptorum Group Limited APM prepares to release earnings report on 19 Aug 2025.
| Founded: | 2010 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 6.9M | IPO Year: | 2018 |
| Target Price: | N/A | AVG Volume (30 days): | 10.2M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.46 - $7.49 | Next Earning Date: | 08-19-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Aptorum Group Limited News
APM Breaking Stock News: Dive into APM Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Sector Update: Health Care Stocks Climb Late Afternoon
MT Newswires
a month ago
Top Midday Gainers
Associated Press Finance
a month ago
BC-Most Active Stocks
GlobeNewswire
a month ago
Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement
MT Newswires
4 months ago
Aptorum Gets Nasdaq Bid Price Non-Compliance Notice
GlobeNewswire
4 months ago
Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
TipRanks
7 months ago
Aptorum Group to Issue 1.5 Million Class A Shares
MT Newswires
7 months ago
Aptorum Prices $3 Million Registered Direct Offering
Compare APM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APM Aptorum Group Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.